飛利信(300287.SZ):被動減持計劃期滿 楊振華的持股數量未發生變動
格隆匯5月21日丨飛利信(300287.SZ)公佈,公司於2020年10月30日刊登了《關於公司控股股東及一致行動人之楊振華先生被動減持股份預披露公吿》(公吿編號:2020-101),對公司控股股東及一致行動人之楊振華的股份被動減持進行了預披露,擬通過集中競價交易方式、大宗交易方式或深圳證券交易所認可或北京市第一中級人民法院認可的其他合法方式減持。減持公司股份合計不超過4675.14萬股,佔公司總股本的3.26 %。
此次被動減持計劃期限已屆滿。在此次被動減持計劃期間,楊振華的股份數量未發生變動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.